Type 2 Diabetes

FDA expands Omnipod 5 AID system for type 2 diabetes, marking the first AID system approved for both type 1 and type 2 diabetes management.

Dexcom's Stelo, the first OTC glucose sensor, launches in the US on August 26, 2024, offering 15-day wear and HSA/FSA eligibility for as low as $89.99 per 2-pack.

A new study significantly demonstrated semaglutide, but not liraglutide, is associated with suicidal ideation.

A new analysis suggests HbA1c may be more informative to fatty liver disease severity than BMI, and should be included in screenings.

A new real-world study suggests tirzepatide provides greater reductions in mortality, cardiovascular risk, and kidney events than GLP-1 receptor agonists in type 2 diabetes.

Treatment with GLP-1 RAs led to improvements in weight loss, liver function tests, and liver fat in patients with diabetes and MASLD, with hepatic improvements independent of weight loss.

FDA approval for the Simplera™ continuous glucose monitor marks the company's first disposable, all-in-one CGM half the size of previous offerings.

The July 2024 endocrinology month in review recaps a pair of regulatory updates, multiple studies on incretin therapies, and the most recent episodes of our flagship diabetes podcast, Diabetes Dialogue.

New study finds semaglutide may reduce smoking urge in type 2 diabetes patients, decreasing tobacco use disorder medical encounters by up to 32%.

An analysis using records from 40 million US patients highlights the surge in new GLP-1 receptor agonist use, with semaglutide dominating new prescriptions since 2020.

A study found individuals with type 2 diabetes who received less than 7 hours of sleep had 2.6 increased odds of microvascular disease.

The CRL cites requests related to the manufacturing process and the type 1 diabetes indication before the application review can be completed.

A STEP-HFpEF analysis suggests semaglutide 2.4 mg (Wegovy) confers benefit across the spectrum of NYHA functional class among patients with obesity-related HFpEF.

Findings from a meta-analysis examining 12 trials including more than 70,000 patients with diabetes support combining SGLT2 inhibitors and GLP-1 RAs.

A study of 18,000 patients showed tirzepatide (Mounjaro) led to more significant weight loss than semaglutide (Ozempic) in adults with overweight or obesity.

In the endocrinology month in review, we spotlight top news in the endocrinology pipeline and the most important updates from ADA 2024.

Data on outcomes stratified according to baseline use of SGLT2 inhibitors from the FLOW trial were presented at ADA 2024.

The CATALYST trial sheds light on the true prevalence of hypercortisolism among difficult-to-control type 2 diabetes, with data at ADA 2024 shedding light on adrenal abnormalities and presence among subgroups.

Study results highlight the impact of continuous glucose monitoring on glucose control and HbA1c improvements in patients with type 2 diabetes, regardless of treatment regimen.

Teva Pharmaceuticals’ launch of an authorized generic of liraglutide injection 1.8 mg (Victoza) for type 2 diabetes makes it the first-ever generic GLP-1.

In the special on-site ADA 2024 episode, hosts are joined by the ADA's Chief Scientific and Medical Officer Robert Gabbay, MD, PhD, to discuss the newly formed Obesity Association.

An analysis of over 2.5 million patients with type 2 diabetes shows newer GLP-1 RAs are linked to lower HbA1c levels.

Use of LX9211 showed significant benefits for diabetic peripheral neuropathic pain in the phase 2 RELIEF-DPN 1 trial.

Omnipod 5 improved HbA1c from 8.2% to 7.4% in 13 weeks among adults with type 2 diabetes in the SECURE-T2D trial, with a nearly 5-hour increase in time in range per day.

Participants assigned to a 4-day energy balance diet plus oral bisphenol A administration at 50 μg/kg body weight experienced significant decreases in peripheral insulin sensitivity.

In retrospective, observational research at ADA 2024, real-world weight loss was linked to a reduction in the risk of obesity-related cancers.

A first-time trial presented at ADA 2024 found the common cholesterol-lowering drug halts vision loss in patients with diabetic eye disease.

This episode covers the clearance of 2 new OTC CGMs from Abbott, JDRF becoming Breakthrough T1D, and the FDA clearance of the CamAPS FX for people with T1D

A propensity score matched analysis suggests use of SGLT2 inhibitors could reduce risk of negative outcomes in patients with systemic lupus erythematosus and type 2 diabetes.

At Heart in Diabetes, full results of the GRACE trial detailed the benefits of relacorilant use from both parts of the 2-part, phase 3 trial.